Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians
暂无分享,去创建一个
S. Yusuf | Sonia S Anand | J. Otvos | A. Sniderman | A. Mente | M. McQueen | K. Schulze | S. Rashid | M. Melone | P. Brown
[1] Salim Yusuf,et al. Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study , 2014, European journal of preventive cardiology.
[2] V. Beral,et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index , 2013, European journal of preventive cardiology.
[3] Samia Mora,et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.
[4] R. Collins,et al. Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.
[5] R. Krauss,et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S] , 2012, Journal of Lipid Research.
[6] A. Goldberg,et al. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk , 2012, Diabetes, obesity & metabolism.
[7] Ming-Dauh Wang,et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.
[8] J. Mckenney,et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. , 2011, American heart journal.
[9] S. Yusuf,et al. Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE) , 2011, PloS one.
[10] JustinaCostandi,et al. Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin Signaling , 2011 .
[11] A. van Tol,et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. , 2011, The Journal of clinical endocrinology and metabolism.
[12] B. Gersh. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease , 2011 .
[13] S. Lear,et al. Ethnic‐Specific Differences in Abdominal Subcutaneous Adipose Tissue Compartments , 2010, Obesity.
[14] A. Kontush,et al. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities , 2010, Current opinion in lipidology.
[15] G. Lip,et al. Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. , 2010, Atherosclerosis.
[16] A. Kontush,et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.
[17] Tom R. Gaunt,et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.
[18] N. Burtt,et al. Association of Blood Lipids With Common DNA Sequence Variants at 19 Genetic Loci in the Multiethnic United States National Health and Nutrition Examination Survey III , 2009, Circulation. Cardiovascular genetics.
[19] J. Falko,et al. Dyslipidemia in South Asians living in a western community. , 2009, Journal of clinical lipidology.
[20] J. Kastelein,et al. Obesity and dyslipidemia. , 2008, Endocrinology and metabolism clinics of North America.
[21] H. Soran,et al. Glycation as an atherogenic modification of LDL , 2008, Current opinion in lipidology.
[22] Yi Zhang,et al. Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles: A Mechanism for High-Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia , 2008, Circulation research.
[23] Martin Adiels,et al. Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[24] D. Rader,et al. Is the cholesteryl ester transfer protein proatherogenic or antiatherogenic in humans? , 2007, Journal of the American College of Cardiology.
[25] M. Deepa,et al. The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. , 2007, Journal of the cardiometabolic syndrome.
[26] S. Lear,et al. Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). , 2007, The American journal of clinical nutrition.
[27] Udo Hoffmann,et al. Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study , 2007, Circulation.
[28] J. Després,et al. Cardiovascular disease under the influence of excess visceral fat. , 2007, Critical pathways in cardiology.
[29] D. Rader,et al. Obesity and atherogenic dyslipidemia. , 2007, Gastroenterology.
[30] R. Bhopal,et al. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. , 2007, International journal of epidemiology.
[31] S. Yusuf,et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. , 2007, JAMA.
[32] M. Chapman. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. , 2006, Pharmacology & therapeutics.
[33] F. Karpe,et al. Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone , 2006, Diabetologia.
[34] S. Verma,et al. South Asians and cardiovascular risk: what clinicians should know. , 2006, Circulation.
[35] J. Borén,et al. Diabetic dyslipidaemia , 2006, Current opinion in lipidology.
[36] S. Brister,et al. Is South Asian ethnicity an independent cardiovascular risk factor? , 2006, The Canadian journal of cardiology.
[37] P. Barter,et al. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. , 2006, Journal of the American College of Cardiology.
[38] P. Barter,et al. High-density lipoproteins as therapeutic targets , 2005, Current opinion in lipidology.
[39] Steven Hawken,et al. Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .
[40] R. Peters,et al. Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.
[41] R. Dullaart,et al. Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.
[42] S. Lear,et al. Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. , 2003, Metabolism: clinical and experimental.
[43] G. Lewis,et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. , 2003, Clinical biochemistry.
[44] D. Rader,et al. Expression of Human Hepatic Lipase in the Rabbit Model Preferentially Enhances the Clearance of Triglyceride‐Enriched Versus Native High‐Density Lipoprotein Apolipoprotein A‐I , 2003, Circulation.
[45] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[46] G. Lewis,et al. Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit , 2002, Circulation.
[47] S. Kaser,et al. Relationship Between Cholesteryl Ester Transfer Protein and Atherogenic Lipoprotein Profile in Morbidly Obese Women , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[48] R. Krauss,et al. Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 , 2002, Journal of Lipid Research.
[49] G. Lewis,et al. Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[50] G. Lewis,et al. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. , 2002, Journal of diabetes and its complications.
[51] S. Yusuf,et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.
[52] A. van Tol,et al. Proatherogenic Role of Elevated CE Transfer From HDL to VLDL1 and Dense LDL in Type 2 Diabetes: Impact of the Degree of Triglyceridemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[53] S. Yusuf,et al. Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). , 2000, Indian heart journal.
[54] A. Tall,et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. , 1999, Journal of lipid research.
[55] G. Lewis,et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. , 1999, The Journal of clinical investigation.
[56] E. Bruckert,et al. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. , 1998, European heart journal.
[57] C. Mann,et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. , 1991, The Journal of clinical investigation.